RedHill reports wider first-half loss amid commercial-portfolio transition
RedHill Biopharma ($RDHL) reported a first-half net loss of $6.1 million, compared with $4.1 million a year earlier, and no revenue from continuing operations. Operating cash use was $4.6 million, while the half-year cash balance stood at $5.3 million. The presentation reflects the transfer of Talicia’s commercial operations into a joint venture, rather than a like-for-like measure of the former consolidated product business. The results provide a financial baseline for RedHill’s subsequent port
0